Patient Education Sheet Library
Search Results
Epcoritamab and GemOx
Epcoritamab and GemOx (gemcitabine and oxaliplatin) is used for diffuse large B-cell lymphoma (DLBCL).
Treatment Given by Infusion Treatment Given by InjectionDownloads:
Download (English)Glofitamab and GemOx
Glofitamab and GemOx (gemcitabine and oxaliplatin) is used for diffuse large B-cell lymphoma (DLBCL).
Treatment Given by Infusion Treatment Given by InjectionDownloads:
Rituximab, Cyclophosphamide, Vincristine and Prednisone
The combination of rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) is used for Non-Hodgkin lymphoma (NHL).
Treatment Given by Infusion Treatment Given by InjectionDownloads:
Teclistamab and Talquetamab
The combination of teclistamab and talquetamab is used for multiple myeloma (MM).
Treatment Given by InjectionDownloads:
Cladribine and Rituximab
Cladribine and rituximab is used for hairy cell leukemia (HCL).
Treatment Given by Infusion Treatment Given by InjectionDownloads:
Ibrutinib and Rituximab
The combination of ibrutinib and rituximab is used for chronic lymphocytic leukemia (CLL), small lymphocytic…
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Acalabrutinib and BR
The combination of acalabrutinib, bendamustine, and rituximab is used for mantle cell lymphoma (MCL).
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Lenalidomide and Rituximab
The combination of lenalidomide and rituximab (R2) is used for follicular lymphoma or marginal zone…
Treatment Given by Infusion Treatment Given by Injection Treatment Taken by MouthDownloads:
Daratumumab and CyBorD
The comination of daratumumab, cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) is used for multiple myeloma and…
Treatment Given by Infusion Treatment Given by InjectionDownloads:
Cladribine
Cladribine is used for hairy cell leukemia.
Treatment Given by Infusion Treatment Given by InjectionDownloads:
Popular Searches
PES Review Committee
The Patient Education Sheet (PES) Committee is a multidisciplinary team of oncology professionals who guide the development and review of these important resources. This committee ensures that every PES is accurate, clear, and meaningful for patients and caregivers navigating cancer treatment.
Led by NCODA and supported through collaboration with three leading professional organizations—ACCC, HOPA, and ONS—the committee combines expertise from across the oncology care spectrum. Together, they uphold best practices, promote consistency in patient education, and remain committed to improving outcomes through accessible, patient-centered information.
